Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages

Online download statistics by month:

Online download statistics by month: March 2021 to March 2024

	Abstract	Full	Pdf
Mar 2021	727	727	510
Apr 2021	455	455	174
May 2021	393	393	104
Jun 2021	257	257	96
Jul 2021	199	200	80
Aug 2021	200	200	87
Sep 2021	153	153	73
Oct 2021	188	188	127
Nov 2021	172	173	76
Dec 2021	141	141	60
Jan 2022	123	125	64
Feb 2022	112	118	112
Mar 2022	133	136	111
Apr 2022	133	136	68
May 2022	153	154	119
Jun 2022	136	143	78
Jul 2022	192	195	80
Aug 2022	250	254	106
Sep 2022	254	256	146
Oct 2022	144	146	80
Nov 2022	142	149	86
Dec 2022	107	109	60
Jan 2023	98	99	53
Feb 2023	129	131	63
Mar 2023	168	171	85
Apr 2023	103	103	79
May 2023	136	137	69
Jun 2023	96	96	52
Jul 2023	108	108	73
Aug 2023	80	81	45
Sep 2023	101	101	50
Oct 2023	133	134	74
Nov 2023	146	146	68
Dec 2023	136	138	91
Jan 2024	131	131	90
Feb 2024	139	139	66
Mar 2024	125	126	98
Total	6593	6649	3553